Cited by 164Fibroblast Growth Factor ResearchAdipokines, Inflammation, and Metabolic DiseasesDiabetes Treatment and Management

The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.

FGF21-based pharmacotherapy – potential utility for metabolic disorders

Gimeno, Ruth E., Moller, David E.·2014·Trends in Endocrinology & Metabolism

DOI 10.1016/j.tem.2014.03.001

Open this paper in CoChat — free account

Abstract

Currently available therapies for diabetes or obesity produce modest efficacy and are usually used in combination with agents targeting cardiovascular risk factors. Fibroblast growth factor 21 (FGF21) is a circulating protein with pleiotropic metabolic actions; pharmacological doses of FGF21 produce anti-diabetic, lipid-lowering, and weight-reducing effects in rodents. Several potential benefits have translated to non-human primates and obese humans with type 2 diabetes (T2D). Accumulating results point to a specific receptor complex and actions in adipose tissue, liver, and brain; several pathways lead to enhanced fatty acid oxidation, increased insulin sensitivity, and augmented energy expenditure. A range of strategies are being explored to derive potent, safe, and convenient therapies which could potentially represent novel approaches to prevent and treat a variety of metabolic disorders.

Integrity signals

Registry

Crossref · 10.1016/j.tem.2014.03.001

Cites

82 of 82 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

FGF-21 as a novel metabolic regulator
Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., Sandusky, G. E., Hammond, L. J., Moyers, J. S., Owens, R. A., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23606 · Cited by 2,125
Endocrine Regulation of the Fasting Response by PPARα-Mediated Induction of Fibroblast Growth Factor 21
Inagaki, T., Dutchak, P., Zhao, G., Ding, X., Gautron, L., Parameswara, V., Li, Y., Goetz, R., Mohammadi, M., Esser, V., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.003 · Cited by 1,504
Hepatic Fibroblast Growth Factor 21 Is Regulated by PPARα and Is a Key Mediator of Hepatic Lipid Metabolism in Ketotic States
Badman, M. K., Pissios, P., Kennedy, A. R., Koukos, G., Flier, J. S., & Maratos-Flier, E. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.002 · Cited by 1,495
FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis
Fisher, F. M., Kleiner, S., Douris, N., Fox, E. C., Mepani, R. J., Verdeguer, F., Wu, J., Kharitonenkov, A., Flier, J. S., Maratos-Flier, E., et al. (2012) · Genes & Development · doi:10.1101/gad.177857.111 · Cited by 1,478
Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice
Xu, J., Lloyd, D. J., Hale, C., Stanislaus, S., Chen, M., Sivits, G., Vonderfecht, S., Hecht, R., Li, Y.-S., Lindberg, R. A., et al. (2009) · Diabetes · doi:10.2337/db08-0392 · Cited by 1,151
Fibroblast Growth Factor 21 Corrects Obesity in Mice
Coskun, T., Bina, H. A., Schneider, M. A., Dunbar, J. D., Hu, C. C., Chen, Y., Moller, D. E., & Kharitonenkov, A. (2008) · Endocrinology · doi:10.1210/en.2008-0816 · Cited by 1,031
Self-citation
The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes
Gaich, G., Chien, J. Y., Fu, H., Glass, L. C., Deeg, M. A., Holland, W. L., Kharitonenkov, A., Bumol, T., Schilske, H. K., & Moller, D. E. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.08.005 · Cited by 885
Self-citation
Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State
Fisher, F. M., Chui, P. C., Antonellis, P. J., Bina, H. A., Kharitonenkov, A., Flier, J. S., & Maratos-Flier, E. (2010) · Diabetes · doi:10.2337/db10-0193 · Cited by 830
Irisin and FGF21 are cold-induced endocrine activators of brown fat function in humans
Lee, P., Linderman, J. D., Smith, S., Brychta, R. J., Wang, J., Idelson, C., Perron, R. M., Werner, C. D., Phan, G. Q., Kammula, U. S., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2013.12.017 · Cited by 802
Autophagy deficiency leads to protection from obesity and insulin resistance by inducing Fgf21 as a mitokine
Kim, K. H., Jeong, Y. T., Oh, H., Kim, S. H., Cho, J. M., Kim, Y.-N., Kim, S. S., Kim, D. H., Hur, K. Y., Kim, H. K., et al. (2013) · Nature Medicine · doi:10.1038/nm.3014 · Cited by 774

Show all 82 references

Sorted by citations

Mechanisms of Insulin Action and Insulin Resistance
Petersen, M. C., & Shulman, G. I. (2018) · Physiological Reviews · doi:10.1152/physrev.00063.2017 · Cited by 3,028
Understanding the Physiology of FGF21
Fisher, F. M., & Maratos-Flier, E. (2016) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021115-105339 · Cited by 912
Targeting adipose tissue in the treatment of obesity-associated diabetes
Kusminski, C. M., Bickel, P. E., & Scherer, P. E. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.75 · Cited by 678
A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects
Talukdar, S., Zhou, Y., Li, D., Rossulek, M., Dong, J., Somayaji, V., Weng, Y., Clark, R., Lanba, A., Owen, B. M., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.02.001 · Cited by 496
Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23
Degirolamo, C., Sabbà, C., & Moschetta, A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.9 · Cited by 424
DRP1-mediated mitochondrial shape controls calcium homeostasis and muscle mass
Favaro, G., Romanello, V., Varanita, T., Andrea Desbats, M., Morbidoni, V., Tezze, C., Albiero, M., Canato, M., Gherardi, G., De Stefani, D., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10226-9 · Cited by 398
FGF21 Regulates Sweet and Alcohol Preference
Talukdar, S., Owen, B. M., Song, P., Hernandez, G., Zhang, Y., Zhou, Y., Scott, W. T., Paratala, B., Turner, T., Smith, A., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.008 · Cited by 342
FGF21 Lowers Plasma Triglycerides by Accelerating Lipoprotein Catabolism in White and Brown Adipose Tissues
Schlein, C., Talukdar, S., Heine, M., Fischer, A. W., Krott, L. M., Nilsson, S. K., Brenner, M. B., Heeren, J., & Scheja, L. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.01.006 · Cited by 252
The Sweet Path to Metabolic Demise: Fructose and Lipid Synthesis
Herman, M. A., & Samuel, V. T. (2016) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.06.005 · Cited by 259
Fructose ingestion acutely stimulates circulating FGF21 levels in humans
Dushay, J. R., Toschi, E., Mitten, E. K., Fisher, F. M., Herman, M. A., & Maratos-Flier, E. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2014.09.008 · Cited by 233
Browning of White Fat: Novel Insight Into Factors, Mechanisms, and Therapeutics: FAT BROWNING AND THEIR POTENTIAL AS THERAPEUTICS
Jeremic, N., Chaturvedi, P., & Tyagi, S. C. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25450 · Cited by 211
Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis
BonDurant, L. D., & Potthoff, M. J. (2018) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071816-064800 · Cited by 222
A liver stress-endocrine nexus promotes metabolic integrity during dietary protein dilution
Maida, A., Zota, A., Sjøberg, K. A., Schumacher, J., Sijmonsma, T. P., Pfenninger, A., Christensen, M. M., Gantert, T., Fuhrmeister, J., Rothermel, U., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85946 · Cited by 170
FGF19 and FGF21 serum concentrations in human obesity and type 2 diabetes behave differently after diet- or surgically-induced weight loss
Gómez‐Ambrosi, J., Gallego-Escuredo, J. M., Catalán, V., Rodrı́guez, A., Domingo, P., Moncada, R., Valentí, V., Salvador, J., Giralt, M., Villarroya, F., et al. (2016) · Clinical Nutrition · doi:10.1016/j.clnu.2016.04.027 · Cited by 168
Fibroblast Activation Protein Cleaves and Inactivates Fibroblast Growth Factor 21
Dunshee, D. R., Bainbridge, T. W., Kljavin, N. M., Zavala-Solorio, J., Schroeder, A. C., Chan, R., Corpuz, R., Wong, M., Zhou, W., Deshmukh, G., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.710582 · Cited by 158
Astaxanthin attenuates hepatic damage and mitochondrial dysfunction in non‐alcoholic fatty liver disease by up‐regulating the FGF21/PGC‐1α pathway
Wu, L., Mo, W., Feng, J., Li, J., Yu, Q., Li, S., Zhang, J., Chen, K., Ji, J., Dai, W., et al. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15099 · Cited by 154
Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non-human primates
Kim, A. M., Somayaji, V. R., Dong, J. Q., Rolph, T. P., Weng, Y., Chabot, J. R., Gropp, K. E., Talukdar, S., & Calle, R. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13023 · Cited by 145
Metabolic Targets in Nonalcoholic Fatty Liver Disease
Esler, W. P., & Bence, K. K. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2019.04.007 · Cited by 145
Fibroblast Growth Factor Signaling in Metabolic Regulation
Nies, V. J. M., Sancar, G., Liu, W., van Zutphen, T., Struik, D., Yu, R. T., Atkins, A. R., Evans, R. M., Jonker, J. W., & Downes, M. (2016) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00193 · Cited by 137
Inflammation initiates a vicious cycle between obesity and nonalcoholic fatty liver disease
Luo, Y., & Lin, H. (2020) · Immunity Inflammation and Disease · doi:10.1002/iid3.391 · Cited by 132
Mechanisms by Which Skeletal Muscle Myokines Ameliorate Insulin Resistance
Balakrishnan, R., & Thurmond, D. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094636 · Cited by 143
Circulating FGF21 proteolytic processing mediated by fibroblast activation protein
Zhen, E. Y., Jin, Z., Ackermann, B. L., Thomas, M. K., & Gutierrez, J. A. (2016) · Biochemical Journal · doi:10.1042/bj20151085 · Cited by 123
Fibroblast growth factor 21: a regulator of metabolic disease and health span
Xie, T., & Leung, P. S. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00101.2017 · Cited by 121
Regulation of longevity by FGF21: interaction between energy metabolism and stress responses
Salminen, A., Kaarniranta, K., & Kauppinen, A. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.05.004 · Cited by 121
FGF21 activates AMPK signaling: impact on metabolic regulation and the aging process
Salminen, A., Kauppinen, A., & Kaarniranta, K. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1477-1 · Cited by 121
FGF21 Revolutions: Recent Advances Illuminating FGF21 Biology and Medicinal Properties
Kharitonenkov, A., & DiMarchi, R. D. (2015) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2015.09.007 · Cited by 114
Hepatokines: unlocking the multi-organ network in metabolic diseases
Iroz, A., Couty, J.-P., & Postic, C. (2015) · Diabetologia · doi:10.1007/s00125-015-3634-4 · Cited by 111
Fibroblast Growth Factor 21 (FGF21) Protects against High Fat Diet Induced Inflammation and Islet Hyperplasia in Pancreas
Singhal, G., Fisher, F. M., Chee, M. J. S., Tan, T. G., Ouaamari, A. E., Adams, A. C., Najarían, R. M., Kulkarni, R., Benoist, C. O., Flier, J. S., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0148252 · Cited by 112
From chronic overnutrition to metaflammation and insulin resistance: adipose tissue and liver contributions
Caputo, T., Gilardi, F., & Desvergne, B. (2017) · FEBS Letters · doi:10.1002/1873-3468.12742 · Cited by 112
Pharmacokinetics and pharmacodynamics of PF‐05231023, a novel long‐acting FGF21 mimetic, in a first‐in‐human study
Dong, J. Q., Rossulek, M. I., Somayaji, V. R., Baltrukonis, D. J., Liang, Y., Hudson, K. J., Hernandez‐Illas, M., & Calle, R. A. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12676 · Cited by 100
A long‐acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non‐alcoholic steatohepatitis partly through an FGF21‐adiponectin‐IL17A pathway
Bao, L., Yin, J., Gao, W. Y., Wang, Q., Yao, W., & Gao, X. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14383 · Cited by 95
Fast and facile synthesis of amidine-incorporated degradable lipids for versatile mRNA delivery in vivo
Han, X., Alameh, M., Gong, N., Xue, L., Ghattas, M., Bojja, G., Xu, J., Zhao, G., Warzecha, C. C., Padilla, M. S., et al. (2024) · Nature Chemistry · doi:10.1038/s41557-024-01557-2 · Cited by 100
Fibroblast Growth Factor 21 and the Adaptive Response to Nutritional Challenges
Martínez‐Garza, Ú., Torres‐Oteros, D., Yarritu, A., Marrero, P. F., Haro, D., & Relat, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194692 · Cited by 88
The significance of beige and brown fat in humans
Kiefer, F. W. (2017) · Endocrine Connections · doi:10.1530/ec-17-0037 · Cited by 82
Mechanisms linking adipose tissue inflammation to cardiac hypertrophy and fibrosis
Anthony, S., Guarnieri, A., Gozdiff, A., Helsley, R. N., Owens, A. P., & Tranter, M. (2019) · Clinical Science · doi:10.1042/cs20190578 · Cited by 82
In situ combinatorial synthesis of degradable branched lipidoids for systemic delivery of mRNA therapeutics and gene editors
Han, X., Xu, J., Xu, Y., Alameh, M., Xue, L., Gong, N., El-Mayta, R. D., Palanki, R., Warzecha, C. C., Zhao, G., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45537-z · Cited by 85
Orosomucoid 2 maintains hepatic lipid homeostasis through suppression of de novo lipogenesis
Zhou, B., Luo, Y., Ji, N., Hu, C., & Lu, Y. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00627-4 · Cited by 75
miR‐212 downregulation contributes to the protective effect of exercise against non‐alcoholic fatty liver via targeting FGF ‐21
Xiao, J., Bei, Y., Liu, J., Dimitrova‐Shumkovska, J., Kuang, D., Zhou, Q., Li, J., Yang, Y., Xiang, Y., Wang, F., et al. (2015) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12733 · Cited by 75
Target acquired: Selective autophagy in cardiometabolic disease
Evans, T. D., Sergin, I., Zhang, X., & Razani, B. (2017) · Science Signaling · doi:10.1126/scisignal.aag2298 · Cited by 74
Adipose tissue dysfunction disrupts metabolic homeostasis: mechanisms linking fat dysregulation to disease
Matar, D. B., Zhra, M., Nassar, W. K., Altemyatt, H., Naureen, A., Abotouk, N., Elahi, M. A., & Aljada, A. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1592683 · Cited by 93
Fibroblast Growth Factor 21 Analogs for Treating Metabolic Disorders
Zhang, J., & Li, Y. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00168 · Cited by 70
Pharmacokinetics (PK), Pharmacodynamics (PD) and Integrated PK/PD Modeling of a Novel Long Acting FGF21 Clinical Candidate PF-05231023 in Diet-Induced Obese and Leptin-Deficient Obese Mice
Weng, Y., Chabot, J., Bernardo, B. L., Yan, Q., Zhu, Y., Brenner, M. B., Vage, C., Logan, A., Calle, R. A., & Talukdar, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119104 · Cited by 67
FGF21 Is an Insulin-Dependent Postprandial Hormone in Adult Humans
Samms, R. J., Lewis, J. E., Norton, L., Stephens, F. B., Gaffney, C. J., Butterfield, T., Smith, D. P., Cheng, C. C., Perfield, J. W., Adams, A. C., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01257 · Cited by 65
Role of Human Brown Fat in Obesity, Metabolism and Cardiovascular Disease: Strategies to Turn Up the Heat
Ruiz, J. R., Martínez‐Téllez, B., Sánchez‐Delgado, G., Osuna‐Prieto, F. J., Rensen, P. C. N., & Boon, M. R. (2018) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2018.07.002 · Cited by 68
The Impact of Organokines on Insulin Resistance, Inflammation, and Atherosclerosis
Choi, K. M. (2016) · Endocrinology and Metabolism · doi:10.3803/enm.2016.31.1.1 · Cited by 62
Hepatocyte-specific fibroblast growth factor 21 overexpression ameliorates high-fat diet-induced obesity and liver steatosis in mice
Yano, K., Yamaguchi, K., Seko, Y., Okishio, S., Ishiba, H., Tochiki, N., Takahashi, A., Kataoka, S., Okuda, K., Liu, Y. X., et al. (2021) · Laboratory Investigation · doi:10.1038/s41374-021-00680-9 · Cited by 63
FGF21 improves glucose homeostasis in an obese diabetes-prone mouse model independent of body fat changes
Laeger, T., Baumeier, C., Wilhelmi, I., Würfel, J., Kamitz, A., & Schürmann, A. (2017) · Diabetologia · doi:10.1007/s00125-017-4389-x · Cited by 59
Macronutrient Intake–Associated FGF21 Genotype Modifies Effects of Weight-Loss Diets on 2-Year Changes of Central Adiposity and Body Composition: The POUNDS Lost Trial
Heianza, Y., Ma, W., Huang, T., Wang, T., Zheng, Y., Smith, S. R., Bray, G. A., Sacks, F. M., & Qi, L. (2016) · Diabetes Care · doi:10.2337/dc16-1111 · Cited by 60
TNP [N2-(m-Trifluorobenzyl), N6-(p-nitrobenzyl)purine] ameliorates diet induced obesity and insulin resistance via inhibition of the IP6K1 pathway
Ghoshal, S., Zhu, Q., Asteian, A., Lin, H., Xu, H., Ernst, G. E., Barrow, J. C., Xu, B., Cameron, M. D., Kamenecka, T. M., et al. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.08.008 · Cited by 58
Alternate-day fasting alleviates diabetes-induced glycolipid metabolism disorders: roles of FGF21 and bile acids
Zhang, H., Zhang, W., Yun, D., Li, L., Zhao, W., Li, Y., Liu, X., & Liu, Z. (2020) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2020.108403 · Cited by 60
Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials
Connolly, J. J., Ooka, K., & Lim, J. K. (2018) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2017.00056 · Cited by 58
Research Perspectives on the Regulation and Physiological Functions of FGF21 and its Association with NAFLD
Inagaki, T. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00147 · Cited by 55
Unlock the Thermogenic Potential of Adipose Tissue: Pharmacological Modulation and Implications for Treatment of Diabetes and Obesity
Peng, X., Gennemark, P., O’Mahony, G., & Bartesaghi, S. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00174 · Cited by 49
Fibroblast growth factor 21 analogue LY2405319 lowers blood glucose in streptozotocin‐induced insulin‐deficient diabetic mice by restoring brown adipose tissue function
Kim, J. H., Bae, K., Choi, Y. ‐., Go, Y., Choe, M., Jeon, Y. ‐., Lee, H.-M., Koo, S., Perfield, J. W., Harris, R. A., et al. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12408 · Cited by 51
CCL5/RANTES contributes to hypothalamic insulin signaling for systemic insulin responsiveness through CCR5
Chou, S., Ajoy, R., Changou, C. A., Hsieh, Y.-T., Wang, Y.-K., & Hoffer, B. J. (2016) · Scientific Reports · doi:10.1038/srep37659 · Cited by 49
FGF21 does not require interscapular brown adipose tissue and improves liver metabolic profile in animal models of obesity and insulin-resistance
Bernardo, B. L., Lu, M. M., Bandyopadhyay, G. K., Li, P., Zhou, Y., Huang, J. S., Levin, N., Tomás, E., Calle, R. A., Erion, D. M., et al. (2015) · Scientific Reports · doi:10.1038/srep11382 · Cited by 49
Fibroblast growth factor 21 is required for beneficial effects of exercise during chronic high-fat feeding
Loyd, C., Magrisso, I. J., Haas, M., Balusu, S., Krishna, R., Itoh, N., Sandoval, D. A., Pérez–Tilve, D., Obici, S., & Habegger, K. M. (2016) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00456.2016 · Cited by 49
Lyophilized Maqui (Aristotelia chilensis) Berry Induces Browning in the Subcutaneous White Adipose Tissue and Ameliorates the Insulin Resistance in High Fat Diet-Induced Obese Mice
Sandoval, V., Femenias, A., Martínez‐Garza, Ú., Sanz‐Lamora, H., Castagnini, J. M., Quifer‐Rada, P., Lamuela-Raventós, R. M., Marrero, P. F., Haro, D., & Relat, J. (2019) · Antioxidants · doi:10.3390/antiox8090360 · Cited by 46
Circadian Rhythm in Adipose Tissue: Novel Antioxidant Target for Metabolic and Cardiovascular Diseases
Man, A. W. C., Xia, N., & Li, H. (2020) · Antioxidants · doi:10.3390/antiox9100968 · Cited by 49
FGF21 is not required for glucose homeostasis, ketosis or tumour suppression associated with ketogenic diets in mice
Stemmer, K., Zani, F., Habegger, K. M., Neff, C., Kotzbeck, P., Bauer, M., Yalamanchilli, S., Azad, A., Lehti, M., Martins, P. J. F., et al. (2015) · Diabetologia · doi:10.1007/s00125-015-3668-7 · Cited by 44
Brown adipose tissue: The heat is on the heart
Thoonen, R., Hindle, A. G., & Scherrer‐Crosbie, M. (2016) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00698.2015 · Cited by 46
Preemptive Activation of the Integrated Stress Response Protects Mice From Diet‐Induced Obesity and Insulin Resistance by Fibroblast Growth Factor 21 Induction
Xu, X., Krumm, C. S., So, J., Bare, C. J., Holman, C. D., Gromada, J., Cohen, D. E., & Lee, A. (2018) · Hepatology · doi:10.1002/hep.30060 · Cited by 43
Therapeutic uses of FGFs
Zhang, J., & Li, Y. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.09.007 · Cited by 44
FGF21 ameliorates the neurocontrol of blood pressure in the high fructose-drinking rats
He, J., Zhao, M., Xia, J.-J., Guan, J., Liu, Y., Wang, L.-Q., Song, D.-X., Qu, M.-Y., Zuo, M., Wen, X., et al. (2016) · Scientific Reports · doi:10.1038/srep29582 · Cited by 41
Browning and thermogenic programing of adipose tissue
Kiefer, F. W. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.09.003 · Cited by 41
Sugar-sweetened beverage intake associations with fasting glucose and insulin concentrations are not modified by selected genetic variants in a ChREBP-FGF21 pathway: a meta-analysis
McKeown, N. M., Dashti, H. S., Ma, J., Haslam, D. E., Jong, J. C. K., Smith, C. E., Tanaka, T., Graff, M., Lemaître, R. N., Rybin, D. V., et al. (2017) · Diabetologia · doi:10.1007/s00125-017-4475-0 · Cited by 40
Fibroblast growth factor 21 has no direct role in regulating fertility in female mice
Singhal, G., Douris, N., Fish, A. J., Zhang, X., Adams, A. C., Flier, J. S., Pissios, P., & Maratos-Flier, E. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.05.010 · Cited by 38
Liver Brain Interactions: Focus on FGF21 a Systematic Review
Prida, E., Álvarez-Delgado, S., Pérez-Lois, R., Soto-Tielas, M., Estany‐Gestal, A., Fernø, J., Seoane, L. M., Quiñones, M., & Al–Massadi, O. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113318 · Cited by 40
New adipokines
Fève, B., Bastard, C., Fellahi, S., Bastard, J., & Capeau, J. (2016) · Annales d Endocrinologie · doi:10.1016/j.ando.2016.01.001 · Cited by 38
Biomarkers of Metabolic Syndrome: Biochemical Background and Clinical Significance
Robberecht, H. J., & Hermans, N. (2016) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2015.0113 · Cited by 38
Hepatic posttranscriptional network comprised of CCR4–NOT deadenylase and FGF21 maintains systemic metabolic homeostasis
Morita, M., Siddiqui, N., Katsumura, S., Rouya, C., Larsson, O. S., Nagashima, T., Hekmatnejad, B., Takahashi, A., Kiyonari, H., Zang, M., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1816023116 · Cited by 37
Fibroblast growth factor 21: An emerging pleiotropic regulator of lipid metabolism and the metabolic network
Li, S., Zou, T., Chen, J., Li, J., & You, J. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.06.033 · Cited by 37
Nutritional Ketosis as a Potential Treatment for Alcohol Use Disorder
Mahajan, V. R., Elvig, S. K., Vendruscolo, L. F., Koob, G. F., Darcey, V. L., King, M. T., Kranzler, H. R., Volkow, N. D., & Wiers, C. E. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.781668 · Cited by 34
Modulation of energy balance by fibroblast growth factor 21
Ramos, D. C., & Aguilar-Salinas, C. A. (2016) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2016-0023 · Cited by 36
Prokaryotic soluble expression and purification of bioactive human fibroblast growth factor 21 using maltose-binding protein
Nguyen, A. N., Song, J.-A., Nguyen, M. T., Do, B. H., Kwon, G. G., Park, S. S., Yoo, J., Jang, J., Jin, J., Osborn, M. J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-16167-x · Cited by 33
Glyco-engineered Long Acting FGF21 Variant with Optimal Pharmaceutical and Pharmacokinetic Properties to Enable Weekly to Twice Monthly Subcutaneous Dosing
Weng, Y., Ishino, T., Sievers, A., Talukdar, S., Chabot, J., Tam, A. S. P., Duan, W., Kerns, K. M., Sousa, E. A., He, T., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-22456-w · Cited by 33
Brown Adipose Tissue: A Human Perspective
Boon, M. R., & Lichtenbelt, W. D. V. M. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_11 · Cited by 35
A biparatopic agonistic antibody that mimics fibroblast growth factor 21 ligand activity
Shi, S. Y., Lu, Y., Liu, Z., Stevens, J. L., Murawsky, C. M., Wilson, V., Hu, Z., Richards, W. G., Michaels, M. L., Zhang, J., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.001752 · Cited by 32
KLB gene polymorphism is associated with obesity and non-alcoholic fatty liver disease in the Han Chinese
Ji, F., Liu, Y., Hao, J., Wang, L., Dai, M.-J., Shen, G.-F., & Yan, X. (2019) · Aging · doi:10.18632/aging.102293 · Cited by 31
Fibroblast growth factor 21 as a potential master regulator in metabolic disorders
Velingkar, A., Vuree, S., Prabhakar, P. K., Kalashikam, R. R., Banerjee, A., & Kondeti, S. (2023) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00244.2022 · Cited by 32
Genetic fusion of human FGF21 to a synthetic polypeptide improves pharmacokinetics and pharmacodynamics in a mouse model of obesity
Yin, J., Bao, L., Tian, H., Wang, Q., Gao, X., & Yao, W. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13499 · Cited by 30
Association of plasma FGF21 levels with muscle mass and muscle strength in a national multicentre cohort study: Korean Frailty and Aging Cohort Study
Roh, E., Hwang, S. Y., Yoo, H. J., Baik, S. H., Cho, B., Park, Y. S., Kim, H. J., Lee, S., Kim, B., Jang, H. C., et al. (2021) · Age and Ageing · doi:10.1093/ageing/afab178 · Cited by 31
Mesenchymal Stem Cells Overexpressing FGF21 Preserve Blood-Brain Barrier Integrity in Experimental Ischemic Stroke
Do, P. T., Chuang, D., Wu, C.-C., Huang, C.-Z., Chen, Y., Kang, S.-J., Chiang, Y. H., Hu, C., & Chen, K. (2023) · Translational Stroke Research · doi:10.1007/s12975-023-01196-8 · Cited by 29
Metabolic profiling of follistatin overexpression: a novel therapeutic strategy for metabolic diseases
Singh, R., Pervin, S., Lee, S., Kuo, A., Grijalva, V. R., David, J., Vergnes, L., & Reddy, S. T. (2018) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s159315 · Cited by 29
Fibroblast growth factor 21 and exercise-induced hepatic mitochondrial adaptations
Fletcher, J. A., Linden, M. A., Sheldon, R. D., Meers, G. M.-E., Morris, E. M., Butterfield, A. M., Perfield, J. W., Thyfault, J. P., & Rector, R. S. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00355.2015 · Cited by 28
Mesenchymal stem cells modified by FGF21 and GLP1 ameliorate lipid metabolism while reducing blood glucose in type 2 diabetic mice
Xue, B., Xiao, X., Yu, T., Xiao, X., Xie, J., Ji, Q., Wang, L., Na, T., Meng, S., 耿培亮, et al. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02205-z · Cited by 27
Hepatocyte β‐Klotho regulates lipid homeostasis but not body weight in mice
Kobayashi, K., Tanaka, T., Okada, S., Morimoto, Y., Matsumura, S., Manio, M. C. C., Inoue, K., Kimura, K., Yagi, T., Saito, Y., et al. (2015) · The FASEB Journal · doi:10.1096/fj.15-274449 · Cited by 27
Translational Pharmacology and Physiology of Brown Adipose Tissue in Human Disease and Treatment
Larson, C. J. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2018_184 · Cited by 26
The fibroblast growth factor system in cognitive disorders and dementia
Zhai, W., Zhang, T., Jin, Y., Huang, S., Xu, M., & Pan, J. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1136266 · Cited by 31
Development of a long acting FGF21 analogue-albumin fusion protein and its anti-diabetic effects
Watanabe, H., Miyahisa, M., Chikamatsu, M., Nishida, K., Minayoshi, Y., Takano, M., Ichimizu, S., Kobashigawa, Y., Morioka, H., Maeda, H., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.05.036 · Cited by 24
Fibroblast Growth Factor 21 (Fgf21) Gene Expression Is Elevated in the Liver of Mice Fed a High-Carbohydrate Liquid Diet and Attenuated by a Lipid Emulsion but Is Not Upregulated in the Liver of Mice Fed a High-Fat Obesogenic Diet
Hao, L., Huang, N. K., Ito, K., Sae‐tan, S., Lambert, J. D., & Ross, A. C. (2016) · Journal of Nutrition · doi:10.3945/jn.115.216572 · Cited by 24
Roux-en-Y gastric bypass surgery is effective in fibroblast growth factor-21 deficient mice
Morrison, C. D., Zheng, H., Mumphrey, M. B., Townsend, R. L., Münzberg, H., Ye, J., & Berthoud, H. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.08.005 · Cited by 24
FGF21 Is Associated with Metabolic Effects and Treatment Response in Depressed Bipolar II Disorder Patients Treated with Valproate
Chang, H. H., Chen, P. S., Cheng, Y. W., Wang, T., Yang, Y. K., & Lu, R. (2017) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx093 · Cited by 24
Novel Combinatorial Regimen of Garcinol and Curcuminoids for Non-alcoholic Steatohepatitis (NASH) in Mice
Majeed, M. A., Majeed, S., Nagabhushanam, K., Lawrence, L., & Mundkur, L. (2020) · Scientific Reports · doi:10.1038/s41598-020-64293-w · Cited by 23
Whole-body and adipose tissue-specific mechanisms underlying the metabolic effects of fibroblast growth factor 21 in the Siberian hamster
Lewis, J. E., Monnier, C., Marshall, H. J., Fowler, M. J., Green, R., Cooper, S., Chiotellis, A., Luckett, J., Perkins, A. C., Coşkun, T., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.10.009 · Cited by 25
Mechanistic Investigation of the Preclinical Pharmacokinetics and Interspecies Scaling of PF-05231023, a Fibroblast Growth Factor 21–Antibody Protein Conjugate
Giragossian, C., Vage, C., Li, J., Pelletier, K. B., Piche‐Nicholas, N., Rajadhyaksha, M., Liras, J. L., Logan, A., Calle, R. A., & Weng, Y. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.061713 · Cited by 20
Biology and pathological implications of brown adipose tissue: promises and caveats for the control of obesity and its associated complications
Tapía, P., Fernández‐Galilea, M., Robledo, F., Mardones, P., Galgani, J. E., & Cortés, V. (2017) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.12389 · Cited by 21
Evaluation of Browning Agents on the White Adipogenesis of Bone Marrow Mesenchymal Stromal Cells: A Contribution to Fighting Obesity
Maio, G. D., Alessio, N., Demirsoy, İ. H., Peluso, G., Perrotta, S., Monda, M., & Bernardo, G. D. (2021) · Cells · doi:10.3390/cells10020403 · Cited by 19
Ahnak deficiency attenuates high-fat diet-induced fatty liver in mice through FGF21 induction
Kim, Y. N., Shin, J. H., Kyeong, D. S., Cho, S. Y., Kim, M., Lim, H. J., Jimenez, M. R. R., Kim, I. Y., Lee, M., Bae, Y. S., et al. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00573-3 · Cited by 19
Atypical Diabetes: What Have We Learned and What Does the Future Hold?
Stone, S., Balasubramanyam, A., & Posey, J. E. (2024) · Diabetes Care · doi:10.2337/dci23-0038 · Cited by 20

Authors: Gimeno, R. E., & Moller, D. E.
Affiliations: Eli Lilly (United States) (US)
Corresponding author: Gimeno, Ruth E.
Moller, David E.
ORCID: Moller, David E.
Venue: Trends in Endocrinology & Metabolism
Publisher: Elsevier BV
Published: 2014-06
Volume: 25
Issue: 6
Pages: 303-311
ISSN: 1043-2760 (ISSN-L)
DOI: 10.1016/j.tem.2014.03.001
OpenAlex: W2038863889
Cited by: 163
References: 82
Citations by year: 2026: 4 · 2025: 4 · 2024: 7 · 2023: 8 · 2022: 8 · 2021: 14 · 2020: 15 · 2019: 14 · 2018: 13 · 2017: 16 · 2016: 36 · 2015: 21 · 2014: 3
FWCI: 2.39
Type: journal article
Language: en
Open access: closed
Locations: Trends in Endocrinology and Metabolism (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords: FGF21, type 2 diabetes, obesity, metabolic disorders, antidiabetic therapy, hypolipidemic effect, weight loss, insulin sensitivity, fatty acid oxidation, energy expenditure, adipose tissue, liver, brain, non-human primates
MeSH terms: Animals, Diabetes Mellitus, Type 2, Energy Metabolism, Fibroblast Growth Factors, Humans, Metabolic Diseases, Lipid Metabolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

FGF21-based pharmacotherapy – potential utility for metabolic disorders

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks